In this issue:
Outcomes of transformed lymphomas without ASCT
MRD dynamics after venetoclax-obinutuzumab for CLL
Ibrutinib + venetoclax for first-line treatment of CLL
Frontline treatment and outcomes in elderly AML
Zanubrutinib for R/R MZL
Tafasitamab + lenalidomide in R/R DLBCL
Cladribine + rituximab for HCL variant
Dasatinib + dexamethasone and HSCT in Ph+ ALL
CNS involvement in AML
COVID-19 severity and mortality in CLL
Please login below to download this issue (PDF)